PRAME and acute myeloid leukemia: The CGA preferentially expressed in melanoma antigen (PRAME) was identified as a valid target for AML and other blood cancers (16, 17) and was recently evaluated in a phase 1 TCR-T trial in patients with relapsed or refractory AML, MDS and MM1,.2